HHS Secretary Kennedy Jr. Drafts Policy to Legalize Six Unapproved Peptides via Compounding Pharmacies

Key points

• HHS Secretary Robert F. Kennedy Jr. announced a draft policy on October 28, 2026, granting 'enforcement discretion' for six specific unapproved peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.
• The policy allows licensed compounding pharmacies to prepare these peptides for individual patients, provided they use FDA-registered ingredient makers, obtain lab certificates for raw materials, and report serious side effects.
• The decision follows a July advisory panel vote that recommended allowing these peptides in compounding, a move that contradicted the recommendations of FDA career scientists who cited a lack of safety and efficacy data.
• Kennedy stated the policy aims to provide a 'controlled alternative' to unregulated sellers, while an HHS spokesperson emphasized that the move does not constitute FDA approval or establish clinical safety.
• The draft policy is open for public comment from October 30 to November 13, 2026, and will remain in effect until the FDA finalizes a specific rule regarding compounded peptides, which has not yet been proposed.

Background

This development follows a series of earlier proposals in October 2026 to deregulate unapproved peptides, which had been marketed by online influencers for unproven uses such as anti-aging and muscle building. Previous coverage noted that the FDA had previously clamped down on the growing industry, but Kennedy has publicly advocated for easing restrictions, citing personal use of the drugs. The current policy is part of a broader effort to shift consumer access from illicit gray-market imports to regulated, prescription-based compounding, despite ongoing concerns from public health advocates about the lack of clinical trial data.

How outlets are covering it

The New York Times and STAT emphasize that the move bypasses standard FDA safeguards, such as placebo-controlled trials and cancer risk assessments, and describe it as a unilateral decision that has sparked serious concern among drug safety experts. CBS News highlights the specific safeguards included in the draft policy, such as quality testing and safety reporting, and notes that Kennedy cited a July advisory panel vote to justify the decision. BBC focuses on the cultural context, noting that unregulated peptides have exploded onto the wellness market, particularly among teens on TikTok, and that health experts caution against their use due to unknown long-term effects. While all sources agree on the lack of FDA approval, they differ in emphasis: CBS and HHS officials frame the policy as a safety measure against unregulated sellers, whereas The New York Times and STAT frame it as a dangerous deregulation that undermines regulatory standards.

Why it matters

The policy could significantly alter the landscape of wellness and medical treatments by making unapproved peptides widely available through licensed pharmacies. This could expose millions of patients to substances that have not undergone rigorous safety and efficacy testing, potentially leading to adverse health effects. Conversely, proponents argue that it provides a safer, regulated alternative to the unregulated gray market, where products like retatrutide have been found to contain no active ingredients. The move also signals a shift in federal regulatory priorities, prioritizing patient choice and access over traditional FDA approval processes, which could have long-term implications for drug development and public health standards.

What to watch

The draft policy will be open for public comment until November 13, 2026. After the comment period, HHS is expected to finalize the rule, which will remain in effect until the FDA proposes a specific rule regarding compounded peptides. The FDA has not yet proposed such a rule, so the policy may remain in place for an extended period. Public and industry reactions to the comment period will likely influence the final version of the policy and its long-term impact on the peptide market.